Biospecifics Technologies Corp (BSTC) 25.66 $BSTC
BioSpecifics Technologies Corp. Announces Presentations at Upcoming Investor Conferences
PR Newswire - Mon May 12, 7:00AM CDT
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in the EU, today announced that BioSpecifics' President, Tom Wegman, will present at the following upcoming investor conferences.
BioSpecifics Technologies Corp. Reports First Quarter 2014 Financial Results
PR Newswire - Thu May 08, 7:00AM CDT
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in the EU, today announced its financial results for the first quarter ended March 31, 2014 and provided a corporate update.
BioSpecifics Technologies Corp. to Host Conference Call to Report First Quarter 2014 Financial Results on Thursday, May 8, 2014
PR Newswire - Thu May 01, 7:30AM CDT
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® (collagenase clostridium histolyticum or CCH) in the U.S. and XIAPEX® in the EU, announced today that it will host a conference call and live audio webcast at 8:30 a.m. ET on Thursday, May 8, 2014 to report its first quarter 2014 financial results and provide a corporate update.
Auxilium Pharma Cuts Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 4:20PM CDT
Auxilium Pharma lowered its guidance for 2014 and cut its revenue guidance by $70 million to $380 million - $420 million.
BioSpecifics Technologies Corp. to Present at the 13th Annual Needham Healthcare Conference
PR Newswire - Wed Apr 02, 7:00AM CDT
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in the EU, today announced that BioSpecifics' President, Tom Wegman, will present a corporate overview at the 13th Annual Needham Healthcare Conference.
OncoGenex Pharmaceuticals (OGXI) Soars: Stock Up 6.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 7:51AM CST
OncoGenex Pharmaceuticals, Inc. was a big mover last session, as its shares rose nearly 7% on the day.
BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2013 Financial Results
PR Newswire - Thu Mar 06, 7:00AM CST
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in the EU, today announced its financial results for the fourth quarter and full year ended December 31, 2013 and provided a corporate update.
Auxilium Pharma Beats on Q4 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 10:00AM CST
Revenues were boosted by the recently acquired subsidiary, Actient, as well as higher Xiaflex sales in the U.S.
Zacks Rank #1 Additions for Monday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (strong buy) List for Monday
Alcobra (ADHD) Jumps: Stock Rises 8.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 26, 8:04AM CST
Alcobra Ltd. was a big mover last session, as the company saw its shares rise by over 8% on the day.
Durata Therapeutics (DRTX) Jumps: Stock Rises 6.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 19, 8:21AM CST
Durata Therapeutics, Inc. (DRTX) was a big mover last session, as the company saw its shares rise by over 6% on the day.
Zacks Rank #1 Additions for Friday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 14, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (strong buy) List for Friday
Positive Data on BioSpecifics/ Auxilium's Xiaflex - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 09, 11:10AM CST
BioSpecifics Technologies recently announced encouraging top-line data on Xiaflex from a phase II dose escalation clinical trial for the treatment of human lipoma.
Biotech Stock Roundup: Christmas Gift for UTHR, TSRO Tumbles - Analyst Blog
Arpita Dutt - Zacks Investment Research - Thu Jan 02, 9:48AM CST
Altogether it was a slow week for the biotech sector though companies like UTHR made the headlines.
Update on BioSpecifics/ Auxilium's Xiaflex - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 27, 3:20PM CST
BioSpecifics Technologies is working hard to develop its pipeline .
Pipeline Progress at Auxilium Pharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 16, 2:35PM CST
Auxilium Pharmaceuticals recently dosed its first patient for the phase II study on Xiaflex for the treatment of frozen shoulder syndrome (adhesive capsulitis).
Auxilium Up on Peyronie's Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 09, 9:40AM CST
Xiaflex, currently marketed for Dupuytren's Contracture, gained FDA approval for Peyronie's disease.
Zacks #1 Rank Additions for Monday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 09, 7:30AM CST
Here are 5 stocks added to the Zacks #1 Rank ("strong buy"
List for Monday
BioSpecifics Technologies Corp. (BSTC) in Focus: Stock Moves 6.5% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 09, 7:21AM CST
BioSpecifics Technologies Corp. (BSTC) was a big mover last session, as the company saw its shares rise by roughly 7% on the day.
FDA approves first drug for rare erection disorder
AP - Fri Dec 06, 1:34PM CST
WASHINGTON (AP) — The Food and Drug Administration on Friday approved the first drug to treat an unusual condition that causes painful, curved erections in men.
BioSpecifics Technologies Corp. Announces Presentations at Upcoming Investor Conferences
PR Newswire - Mon May 12, 7:00AM CDT
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in the EU, today announced that BioSpecifics' President, Tom Wegman, will present at the following upcoming investor conferences.
BioSpecifics Technologies Corp. Reports First Quarter 2014 Financial Results
PR Newswire - Thu May 08, 7:00AM CDT
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in the EU, today announced its financial results for the first quarter ended March 31, 2014 and provided a corporate update.
BioSpecifics Technologies Corp. to Host Conference Call to Report First Quarter 2014 Financial Results on Thursday, May 8, 2014
PR Newswire - Thu May 01, 7:30AM CDT
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® (collagenase clostridium histolyticum or CCH) in the U.S. and XIAPEX® in the EU, announced today that it will host a conference call and live audio webcast at 8:30 a.m. ET on Thursday, May 8, 2014 to report its first quarter 2014 financial results and provide a corporate update.
Auxilium Pharma Cuts Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 4:20PM CDT
Auxilium Pharma lowered its guidance for 2014 and cut its revenue guidance by $70 million to $380 million - $420 million.
BioSpecifics Technologies Corp. to Present at the 13th Annual Needham Healthcare Conference
PR Newswire - Wed Apr 02, 7:00AM CDT
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in the EU, today announced that BioSpecifics' President, Tom Wegman, will present a corporate overview at the 13th Annual Needham Healthcare Conference.
OncoGenex Pharmaceuticals (OGXI) Soars: Stock Up 6.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 7:51AM CST
OncoGenex Pharmaceuticals, Inc. was a big mover last session, as its shares rose nearly 7% on the day.
BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2013 Financial Results
PR Newswire - Thu Mar 06, 7:00AM CST
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in the EU, today announced its financial results for the fourth quarter and full year ended December 31, 2013 and provided a corporate update.
Auxilium Pharma Beats on Q4 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 10:00AM CST
Revenues were boosted by the recently acquired subsidiary, Actient, as well as higher Xiaflex sales in the U.S.
Zacks Rank #1 Additions for Monday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (strong buy) List for Monday
Alcobra (ADHD) Jumps: Stock Rises 8.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 26, 8:04AM CST
Alcobra Ltd. was a big mover last session, as the company saw its shares rise by over 8% on the day.
Durata Therapeutics (DRTX) Jumps: Stock Rises 6.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 19, 8:21AM CST
Durata Therapeutics, Inc. (DRTX) was a big mover last session, as the company saw its shares rise by over 6% on the day.
Zacks Rank #1 Additions for Friday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 14, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (strong buy) List for Friday
Positive Data on BioSpecifics/ Auxilium's Xiaflex - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 09, 11:10AM CST
BioSpecifics Technologies recently announced encouraging top-line data on Xiaflex from a phase II dose escalation clinical trial for the treatment of human lipoma.
Biotech Stock Roundup: Christmas Gift for UTHR, TSRO Tumbles - Analyst Blog
Arpita Dutt - Zacks Investment Research - Thu Jan 02, 9:48AM CST
Altogether it was a slow week for the biotech sector though companies like UTHR made the headlines.
Update on BioSpecifics/ Auxilium's Xiaflex - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 27, 3:20PM CST
BioSpecifics Technologies is working hard to develop its pipeline .
Pipeline Progress at Auxilium Pharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 16, 2:35PM CST
Auxilium Pharmaceuticals recently dosed its first patient for the phase II study on Xiaflex for the treatment of frozen shoulder syndrome (adhesive capsulitis).
Auxilium Up on Peyronie's Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 09, 9:40AM CST
Xiaflex, currently marketed for Dupuytren's Contracture, gained FDA approval for Peyronie's disease.
Zacks #1 Rank Additions for Monday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 09, 7:30AM CST
Here are 5 stocks added to the Zacks #1 Rank ("strong buy"
List for Monday BioSpecifics Technologies Corp. (BSTC) in Focus: Stock Moves 6.5% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 09, 7:21AM CST
BioSpecifics Technologies Corp. (BSTC) was a big mover last session, as the company saw its shares rise by roughly 7% on the day.
FDA approves first drug for rare erection disorder
AP - Fri Dec 06, 1:34PM CST
WASHINGTON (AP) — The Food and Drug Administration on Friday approved the first drug to treat an unusual condition that causes painful, curved erections in men.
